Диссертация (1139759), страница 21
Текст из файла (страница 21)
Diagnostic efficacy of gadoxetic acid-enhanced MRI for thedetection and characterisation of liver metastases: comparison with multidetectorrow CT / Y.K. Kim, G. Park, C.S. Kim [et al] // Br. J. Radiol. – 2012. – V.85(1013). – P.539-547.82.Kim Y.K. Three-dimensional dynamic liver MR imaging using sensitivityencodingfordetectionofhepatocellularcarcinomas:comparisonwithsuperparamagnetic iron oxide-enhancedmr imaging / Y.K. Kim, C.S.
Kim, H.S.Kwak [et al] // J. Magn. Reson. Imaging. – 2004. – V.20 (5). – P. 826-837.83.Kim A. Gadoxetic acid-enhanced 3.0T MRI for the evaluation of hepaticmetastasis from colorectal cancer: metastasis is not always seen as a "defect" onthe hepatobiliary phase / A. Kim, C.H. Lee, B.H. Kim [et al] // Eur. J. Radiol. –2012. – V. 81(12). – P.3998-4004.13284.Kinner S. Diffusion weighted MR imaging in patients with HCC and livercirrhosis after administration of different gadolinium contrast agents: is it stillreliable? / S. Kinner, L. Umutlu, S.
Blex [et al] // Eur. J. Radiol. – 2012. –V.81(4). –P.625-628.85.Kitao A. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging– correlation with molecular transporters andhistopathologic features / A. Kitao , Y. Zen, O. Matsui [et al] // Radiology.
– 2010.– V. 256 (3). – P. 817-826.86.Koh D.M. Diffusion-weighted MRI in the body: applications and challengesin oncology / D.M. Koh, D.J. Collins // Am. J. Roentgenol. – 2007. –V. 188(6). –P.1622-1635.87.Koh D.M. Predicting response of colorectal hepatic metastasis: value ofpretreatment apparent diffusion coefficients / D.M. Koh, E. Scurr, D.J. Collins [etal] // Am. J. Roentgenol. – 2007. – V.188(4). – P.1001-1008.88.Koh J. Intrahepatic mass-forming cholangiocarcinoma: prognostic value ofpreoperative gadoxetic acid-enhanced MRI / J.
Koh, Y.E. Chung, J.H. Nahm [et al]// Eur Radiol. – 2016. – V. 26(2). – P. 407-416.89.Kopetz S. Improved survival in metastatic colorectal cancer is associatedwith adoption of hepatic resection and improved chemotherapy / S. Kopetz, G.J.Chang, M.J. Overman [et al] // J. Clin.
Oncol. – 2009. – V.27(22). – P. 3677-3683.90.Krinsky G.A. Transplantation for hepatocellular carcinoma and cirrhosis:sensitivity of magnetic resonance imaging / G.A. Krinsky, V.S. Lee, N.D. Theise[et al] // Liver Transpl. – 2002. – V. 8 (12). – P. 1156-1164.91.Kudo M.
JSH Consensus-Based Clinical Practice Guidelines for theManagement of Hepatocellular Carcinoma: 2014 Update by the Liver CancerStudy Group of Japan / M. Kudo, O. Matsui, N. Izumi [et al] // Liver Cancer. –2014. – V. 3(3-4). – P. 458-68.92.Laniado M. First use of GdDTPA/dimeglumine in man / M. Laniado, H.J.Weinmann, W. Schörner [et al] // Physiol. Chem. Phys. Med.
NMR. – 1984. –V.16. – P. 157-165.13393.Latif M.A. The role of MR diffusion in differentiation of malignant andbenign hepatic focal lesions / M.A. Latif, G.E. Hawary, A.E. Badrawy [et al] //The Egypt J. of Radiol. and Nuclear Medicine. – 2014. – V. 45(2). – P. 299–308.94.Lauenstein T. Nephrogenic systemic fibrosis risk after liver magneticresonance imaging with gadoxetate disodium in patients with moderate to severerenal impairment: results of a prospective, open-label, multicenter study / T.Lauenstein, F. Ramirez-Garrido, Y.H. Kim [et al] // Invest. Radiol.
– 2015. – V. 50(6). – P. 416-422.95.Laumonier H. Hepatocellular adenomas: magnetic resonance imagingfeatures as a function of molecular pathological classification / H. Laumonier, P.Bioulac-Sage, C. Laurent [et al] // Hepatology. – 2008. – V. 48 (3). – P. 808-818.96.Le Bihan D. MR imaging of intravoxel incoherent motions: application todiffusion and perfusion in neurologic disorders / D. Le Bihan, E. Breton, D.Lallemand [et al] // Radiology. – 1986. – V.161(2).
– P. 401-407.97.Lee S.A. Paradoxical high signal intensity of hepatocellular carcinoma in thehepatobiliary phase of Gd-EOB-DTPA enhanced MRI: initial experience / S.A.Lee, C.H. Lee, W.Y. Jung [et al] // Magn. Reson. Imaging. – 2011. – V. 29 (1).
–P. 83-90.98.Lohrke J. 25 Years of Contrast-Enhanced MRI: Developments, CurrentChallenges and Future Perspectives / J. Lohrke, T. Frenzel, J. Endrikat [et al] //Adv. Ther. – 2016. – V.33(1). – P. 1-28.199. Macera A. Staging of colorectal liver metastases after preoperativechemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPAMRI sequences increases sensitivity and diagnostic accuracy / A. Macera, C. Lario,M. Petracchini [et al] // Eur.
Radiol. – 2013. – V. 23(3). – P. 739-747.100. Matos A. P. Focal liver lesions: Practical magnetic resonance imagingapproach / A. P. Matos, F. Velloni, M. Ramalho [et al] // World J. Hepatol. –2015.– V. 7(16). – P.1987–2008.101. McInnes M.D. Focal Nodular Hyperplasia and Hepatocellular Adenoma:Accuracy of Gadoxetic Acid-enhanced MR Imaging – A Systematic Review /134M.D.
McInnes, R.M. Hibbert, J.R. Inácio [et al] // Radiology – 2015. – V. 277 (2).– P. 413-423.102. Miller F.H. Utility of diffusion-weighted MRI in distinguishing benign andmalignant hepatic lesions / F.H. Miller, N. Hammond, A.J. Siddiqi [et al] // J.Magn. Reson. Imaging.
– 2010. – V. 32(1). – P.138-147.103. Motosugi U. Delay before the hepatocyte phase of Gd-EOB-DTPAenhanced MR imaging: is it possible to shorten the examination time? / U.Motosugi, T. Ichikawa, L. Tominaga [et al] // Eur Radiol. – 2009. – V.19(11).
–P.2623-2629.104. Motosugi U. Distinguishing hypervascular pseudolesions of the liver fromhypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MRimaging / U. Motosugi, T. Ichikawa, H. Sou [et al] // Radiology. – 2010.
– V.256(1). – P.151-158.105. MotosugiU.HepatobiliaryMRcontrastagentsinhypovascularhepatocellular carcinoma / U. Motosugi, P. Bannas, K. Sano [et al] // J. Magn.Reson. Imaging. – 2015. – V. 41 (2). – P. 251-265.106. Muhi A. Diffusion- and T₂-weighted MR imaging of the liver: effect ofintravenous administration of gadoxetic acid disodium / A. Muhi, T. Ichikawa, U.Motosugi [et al] // Magn.
Reson. Med. Sci. – 2012. – V.11(3). – P.185-191.107. Muller M.F. Abdominal diffusion mapping with use of a whole-body echoplanar system / M.F. Muller, P. Prasad, B. Siewert [et al] // Radiology – 1994. –V.190. – P. 475–483.108. Nam S.J. Hepatic cavernous hemangiomas: relationship between speed ofintratumoral enhancement during dynamic MRI and apparent diffusion coefficienton diffusion-weighted imaging / S.J. Nam, K.Y.
Park, J.S. Yu [et al] // Korean J.Radiol. – 2012. – V.13(6). – P. 728-735.109. Nasu K. Hepatic metastases: diffusion-weighted sensitivity-encoding versusSPIO-enhanced MR imaging / K. Nasu, Y. Kuroki, S. Nawano [et al] // Radiology.– 2006. – V.239 (1). – P. 122-130.135110. Oh J.W. Does the Gadoxetic Acid-Enhanced Liver MRI Impact on theTreatment of Patients with Colorectal Cancer? Comparison Study with 18F-FDGPET/CT / J.W.
Oh, S.N. Oh, Jа.I. Choi [et al] // Biomed. Res. Int. –2016:8412071.111. Onishi H. Hypervascular hepatocellular carcinomas: detection withgadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT / H.Onishi, T. Kim, Y. Imai [et al] // Eur.
Radiol. – 2012. – V. 22 (4). – P. 845-54.112. Onur M.R. The role of ADC measurement in differential diagnosis of focalhepatic lesions / M.R. Onur, M. Çiçekçi, A. Kayalı [et al] // Eur. J. Radiol. – 2012.– V.81(3). – P.171-176.113. Papanikolaou N. Comparison between two-point and four-point methods forquantification of apparent diffusion coefficient of normal liver parenchyma andfocal lesions. Value of normalization with spleen / N. Papanikolaou, S.Gourtsoyianni, S. Yarmenitis [et al] // Eur.
J. Radiol. – 2010. – V.73(2). – P. 305309.114. Parikh T. Focal liver lesion detection and characterization with diffusionweighted MR imaging: comparison with standard breath-hold T2-weightedimaging / T. Parikh, S.J. Drew, V.S. Lee [et al] // Radiology. – 2008. – V.246(3). –P.812-822.115.
Park G. Diagnostic efficacy of gadoxetic acid-enhanced MRI in thedetectionofhepatocellularcarcinomas:comparisonwithgadopentetatedimeglumine / G. Park, Y.K. Kim, C.S. Kim [et al] // Br. J. Radiol. - 2010. - V. 83(996). - P. 1010-1016.116. Park H.J. Small intrahepatic mass-forming cholangiocarcinoma: target signon diffusion-weighted imaging for differentiation from hepatocellular carcinoma /H.J. Park, Y.K. Kim, M.J. Park [et al] // Abdom. Imaging – 2013. – V.38(4). – P.793-801.117. Park M.J. Small hepatocellular carcinomas: improved sensitivity bycombining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns /M.J. Park, Y.K.
Kim, M.W. Lee [et al] // Radiology. – 2012. – V. 264(3). – P.761-770.136118. Péporté A.R. Imaging features of intrahepatic cholangiocarcinoma in GdEOB-DTPA-enhanced MRI / A.R. Péporté, W.H. Sommer, K. Nikolaou [et al] //Eur J Radiol. – 2013. – V. 82(3). – P.101-106.119. Qayyum A. Diffusion-weighted imaging in the abdomen and pelvis:concepts and applications / A. Qayyum // Radiographics. – 2009. – V.29(6).
–P.1797-1810.120. Ronot M. Hepatocellular adenomas: accuracy of magnetic resonanceimaging and liver biopsy in subtype classification / M. Ronot, S. Bahrami, J.Calderaro [et al] // Hepatology. – 2011. – V. 53 (4). – P. 1182-1191.121. Runge V.M. Safety of the Gadolinium-Based Contrast Agents for MagneticResonance Imaging, Focusing in Part on Their Accumulation in the Brain andEspecially the Dentate Nucleus / V.M. Runge // Invest. Radiol.
– 2016. – V.51(5).– P. 273-279.122. Runge V.M. The developmental history of the gadolinium chelates asintravenous contrast media for magnetic resonance / V.M. Runge, T. Ai, D. Hao,[et al] // Invest. Radiol. – 2011. – V.46 (12). – P. 807-816.123. Saito K. Effect of Gd-EOB-DTPA on T2-weighted and diffusion-weightedimages for the diagnosis of hepatocellular carcinoma / K. Saito, Y.
Araki, J. Park[et al] // J. Magn. Reson. Imaging. – 2010. – V.32(1). – P. 229-234.124. Sandrasegaran K. The value of diffusion-weighted imaging in characterizingfocal liver masses / K. Sandrasegaran, F.M. Akisik, C. Lin [et al] // Acad. Radiol.– 2009. – V. 16(10). – P. 1208-1214.125. Schaefer P.W. Diffusion-weighted MR imaging of the brain / P.W. Schaefer,P.E. Grant, R.G. Gonzalez // Radiology. – 2000.
– V.217(2). – P.331-345.126. Schmid-Tannwald C. Diffusion-weighted MR imaging of focal liver lesionsin the left and right lobes: is there a difference in ADC values? / C. SchmidTannwald, Y. Jiang, F. Dahi [et al] // Acad. Radiol. – 2013. – V. 20(4). – P.440445.127. Schwope R.B. Gadoxetic acid: pearls and pitfalls / R.B. Schwope, L.A.
May,M.J. Reiter [et al] // Abdom. Imaging. – 2015. – V.40(6). – P. 2012-2029.137128. Song K.D. Detection and characterization of small focal hepatic lesions(≤2.5 cm in diameter): a comparison of diffusion-weighted images before and afteradministration of gadoxetic acid disodium at 3.0T / K.D. Song, Y.K. Kim, W.J.Lee [et al] // Acta Radiol. – 2012. – V. 53(5). – P. 485-493.129. Stoot J.H. Malignant transformation of hepatocellular adenomas intohepatocellular carcinomas: a systematic review including more than 1600 adenomacases / J.H. Stoot, R.J. Coelen, M.C.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
